Little vTv Therapeutics adds another round of bad data on Alzheimer's drug, but they still love their chances
In Alzheimer’s, failure seems to spring eternal, but that doesn’t mean you can’t find something to sell to investors.
We already know that vTv Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
